title: Quality of life in low-grade glioma patients receiving temozolomide.
abstract: The purpose of this study was to describe the quality of life (QOL) of low-grade glioma (LGG) patients at baseline prior to chemotherapy and through 12 cycles of temozolomide (TMZ) chemotherapy. Patients with histologically confirmed LGG with only prior surgery were given TMZ for 12 cycles. QOL assessments by the Functional Assessment of Cancer Therapy-Brain (FACT-Br) were obtained at baseline prior to chemotherapy and at 2-month intervals while receiving TMZ. Patients with LGG at baseline prior to chemotherapy had higher reported social well-being scores (mean difference = 5.0; p < 0.01) but had lower reported emotional well-being scores (mean difference = 2.2; p < 0.01) compared to a normal population. Compared to patients with left hemisphere tumors, patients with right hemisphere tumors reported higher physical well-being scores (p = 0.01): 44% could not drive, 26% did not feel independent, and 26% were afraid of having a seizure. Difficulty with work was noted in 24%. Mean change scores at each chemotherapy cycle compared to baseline for all QOL subscales showed either no significant change or were significantly positive (p < 0.01). Patients with LGG on TMZ at baseline prior to chemotherapy reported QOL comparable to a normal population with the exception of social and emotional well-being, and those with right hemisphere tumors reported higher physical well-being scores compared to those with left hemisphere tumors. While remaining on therapy, LGG patients were able to maintain their QOL in all realms. LGG patients' QOL may be further improved by addressing their emotional well-being and their loss of independence in terms of driving or working.
authors: Department of Medicine, Division of Hematology/Oncology/Neuro-Oncology, University of California, San Francisco, CA 94143-2167, USA. Raymond.Liu@ucsf.edu
authors: Raymond
authors: R
authors: Liu
authors: Karla
authors: K
authors: Solheim
authors: Mei-Yin
authors: MY
authors: Polley
authors: Kathleen R
authors: KR
authors: Lamborn
authors: Margaretta
authors: M
authors: Page
authors: Anne
authors: A
authors: Fedoroff
authors: Jane
authors: J
authors: Rabbitt
authors: Nicholas
authors: N
authors: Butowski
authors: Michael
authors: M
authors: Prados
authors: Susan M
authors: SM
authors: Chang
mesh_terms: D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009837:Oligodendroglioma / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology; D017063:Outcome Assessment, Health Care; D011379:Prognosis; D011446:Prospective Studies; D011788:Quality of Life; D018434:Sickness Impact Profile; D000077204:Temozolomide; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide